Aspirin-exacerbated Respiratory Disease, Nasal Polyp
Conditions
Keywords
Aspirin-exacerbated respiratory disease, Nasal polyp
Brief summary
We hypothesize that the miRNA expression in subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) differs from the miRNA expressed in subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD).
Detailed description
Nasal epithelial tissue will be collected from the inferior nasal turbinates of ten subjects with nasal polyps and AERD disease and from the inferior turbinates of ten subjects with nasal polyps but without AERD. A rhinoprobe™ will be used to collect this epithelial tissue. These samples will be analyzed by miRNA assay to determine if there is a difference in mircroRNA expression between the two subject groups.
Interventions
GENETICmicroRNA
Biological samples will be taken from subjects w/ Nasal polyps & AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
Sponsors
University of South Florida
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Ages eligible for study: 18 to 70 years * Genders eligible for study: male and female * Signed and dated written informed consent is obtained prior to study * Subjects have a physician diagnosis of nasal polyps without AERD or physician diagnosis of nasal polyps with AERD. The diagnosis of aspirin sensitive asthma must be present for a minimum of three months. If the medical history is indeterminate either an aspirin challenge will be required to confirm or rule out the diagnosis. An aspirin challenge is a protocol that can safely be performed as an out patient procedure with close supervision.
Exclusion criteria
* Pregnant and/or lactating females. * Current tobacco use. * Severe psychiatric illness. * Current illicit substance use or dependence and/or abuse of alcohol. * Primary or secondary immunodeficiency. * Any clinically significant uncontrolled medical condition that would put the patient at risk.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Positibe Group: 2 fold or greater will be identified as differntially expressed MiRNA. | No time frame noted | 5 total groups |
| Negative Group: MiRNAs are absent from both groups | No time frame noted | 5 total groups |
Countries
United States
Outcome results
None listed